{"schema_version":"secwatch.filing_event.v1","accession":"0001129928-26-000026","form_type":"8-K","ticker":"ONCY","cik":"0001129928","company_name":"ONCOLYTICS BIOTECH INC","filed_at":"2026-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:31.988667+00:00","generated_at":"2026-05-15T03:43:03.596952+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Oncolytics secures FDA alignment on pivotal anal cancer study for pelareorep","bullets":["FDA agreed on a randomized controlled pivotal trial design for pelareorep in post-first-line metastatic SCAC, targeting accelerated and full approval.","Prior pelareorep+checkpoint data showed median duration of response 15.5 months vs 9.5 months SOC; 12-month survival 82% vs 45.7%.","No FDA-approved therapies exist for SCAC after first-line chemo/checkpoint; over 10,000 US patients affected annually.","Company will finalize protocol using FDA feedback; study enables multiple endpoint assessments for potential simultaneous approvals."],"urls":{"canonical":"https://secwatch.observer/filing/0001129928-26-000026","json":"https://secwatch.observer/filing/0001129928-26-000026.json","markdown":"https://secwatch.observer/filing/0001129928-26-000026.md","text":"https://secwatch.observer/filing/0001129928-26-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000026/0001129928-26-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000026/oncy-20260427.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T03:43:03.596952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001493152-26-026760","ticker":"CING","company_name":"Cingulate Inc.","filed_at":"2026-06-02T12:10:25+00:00","headline":"Cingulate receives FDA Complete Response Letter for CTx-1301; no safety/efficacy issues, CMC-only","event_type":"regulatory","sec_items":["7.01","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026760","json":"https://secwatch.observer/filing/0001493152-26-026760.json","markdown":"https://secwatch.observer/filing/0001493152-26-026760.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1862150/000149315226026760/0001493152-26-026760-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1862150/000149315226026760/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-068659","ticker":"OTLK","company_name":"Outlook Therapeutics, Inc.","filed_at":"2026-06-01T13:15:32+00:00","headline":"Outlook Therapeutics resubmits BLA for ONS-5010 to FDA; Class 1 review, PDUFA in 60 days","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068659","json":"https://secwatch.observer/filing/0001104659-26-068659.json","markdown":"https://secwatch.observer/filing/0001104659-26-068659.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926068659/0001104659-26-068659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926068659/tm2616461d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-062172","ticker":"RR","company_name":"RICHTECH ROBOTICS INC.","filed_at":"2026-05-28T20:49:32+00:00","headline":"Richtech Robotics receives Nasdaq delisting notice for late Q1 10-Q filing","event_type":"regulatory","sec_items":["3.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062172","json":"https://secwatch.observer/filing/0001213900-26-062172.json","markdown":"https://secwatch.observer/filing/0001213900-26-062172.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1963685/000121390026062172/0001213900-26-062172-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1963685/000121390026062172/ea0292546-8k_richtech.htm"},"side_by_side_evidence":null},{"accession":"0001140361-26-022979","ticker":"BBIO","company_name":"BridgeBio Pharma, Inc.","filed_at":"2026-05-27T20:01:34+00:00","headline":"FDA accepts NDA for BBP-418 with Priority Review; PDUFA Nov 27, 2026","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-022979","json":"https://secwatch.observer/filing/0001140361-26-022979.json","markdown":"https://secwatch.observer/filing/0001140361-26-022979.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000114036126022979/0001140361-26-022979-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000114036126022979/ef20074977_8k.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-065992","ticker":"OTLK","company_name":"Outlook Therapeutics, Inc.","filed_at":"2026-05-26T11:15:41+00:00","headline":"FDA grants Outlook Therapeutics appeal; BLA resubmission planned for June 2026","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-065992","json":"https://secwatch.observer/filing/0001104659-26-065992.json","markdown":"https://secwatch.observer/filing/0001104659-26-065992.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926065992/0001104659-26-065992-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926065992/tm2615583d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-060667","ticker":"LRHC","company_name":"La Rosa Holdings Corp.","filed_at":"2026-05-22T21:20:15+00:00","headline":"La Rosa Holdings receives Nasdaq deficiency notice for late 10-K and 10-Q filings","event_type":"regulatory","sec_items":["3.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-060667","json":"https://secwatch.observer/filing/0001213900-26-060667.json","markdown":"https://secwatch.observer/filing/0001213900-26-060667.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1879403/000121390026060667/0001213900-26-060667-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1879403/000121390026060667/ea0291964-8k_larosa.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-064861","ticker":"RGTI","company_name":"Rigetti Computing, Inc.","filed_at":"2026-05-21T11:30:49+00:00","headline":"Rigetti signs LOI for up to $100M CHIPS Act award for quantum R&D; government to receive equity","event_type":"regulatory","sec_items":["3.02","8.01","7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-064861","json":"https://secwatch.observer/filing/0001104659-26-064861.json","markdown":"https://secwatch.observer/filing/0001104659-26-064861.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1838359/000110465926064861/0001104659-26-064861-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1838359/000110465926064861/tm2615300d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-024659","ticker":"NNE","company_name":"Nano Nuclear Energy Inc.","filed_at":"2026-05-20T21:10:43+00:00","headline":"NRC accepts Nano Nuclear's construction permit application for KRONOS MMR at Univ. of Illinois","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-024659","json":"https://secwatch.observer/filing/0001493152-26-024659.json","markdown":"https://secwatch.observer/filing/0001493152-26-024659.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1923891/000149315226024659/0001493152-26-024659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1923891/000149315226024659/form8-k.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}